Clinical Trial Data Managers Lose 12 Hours Weekly to Manual Tasks, Raising Quality Concerns

A comprehensive industry survey has revealed alarming inefficiencies in clinical trial operations, with data managers losing an estimated 12 hours per week per study to manual processes that could compromise data quality in future regulatory submissions.

The Clinical Data Research Report, conducted by Veeva Systems (搜索)搜索该公司 in collaboration with the Society for Clinical Data Management (搜索)搜索该词条 (SCDM (搜索)搜索该词条), surveyed more than 85 data managers and clinical research associates (CRAs) across pharmaceutical sponsors and contract research organizations. The study focused specifically on professionals actively working on Phase III trials to capture current operational realities.

Manual Processes Dominate Daily Workflows

The research identified manual data reconciliation and data review as the most time-consuming tasks facing data managers today. These activities, while necessary for trial integrity, are consuming significant resources that could be redirected toward more strategic activities.

"The two tasks that were flagged as having the most time spent are no shock to anybody: manual reconciliation and data review," explained Manny Vazquez, Senior Director of Clinical Data Strategy at Veeva Systems (搜索)搜索该公司. "Certainly, some of the time they're spending is necessary because those tasks have to be done, so next we need to tease out how much of the time they're spending is 'waste'."

CRAs face similar challenges, reporting excessive time spent updating multiple systems, writing reports, and following up with clinical sites. The survey revealed that 97% of respondents are working outside of clinical systems or using a mix of fragmented systems, creating additional operational complexity.

Data Quality Emerges as Primary Risk

Perhaps most concerning, 70% of survey respondents identified data quality as their number one risk concern. This finding takes on heightened significance given the recent release of ICH E6(R3) guidance and the global regulatory push toward risk-based trial execution.

"If you can't stand by the quality of the data you're submitting to a regulatory body, then you have really, really big problems," Vazquez emphasized. "Particularly with the release of the ICH E6(R3) guidance and the heavy push from virtually every global regulatory body for risk-based trial execution."

The convergence of manual processes, fragmented systems, and data quality concerns suggests that current operational inefficiencies may pose risks to future regulatory submissions and trial outcomes.

Leadership Investment Required for Change

The research highlighted a fundamental disconnect between operational realities and organizational priorities. According to Vazquez, many leadership teams consider existing data review processes as "boxes checked," without fully understanding the scope of inefficiencies or their potential impact.

"[For] data managers, it's not a secret that there is a lot of inefficiency going on, [but] it's never been quantified before," Vazquez noted. "There's no budget for tools like a Clinical Database (CDB) and things that are meant to help streamline and automate that data review process because the leadership doesn't truly realise there is a problem that needs to be solved."

The survey findings suggest that modernization efforts require top-down organizational commitment. "These teams need more modern tools; they need updated SOPs and processes that can take advantage of those tools, and that's going to require investment – it's going to require change management," Vazquez stated.

Evolution of Clinical Research Roles

The research also points toward an evolution in clinical research roles, particularly for CRAs. The emergence of central monitoring teams and remote data review capabilities is reshaping traditional site-based monitoring approaches.

"The CRA of the future is going to be less of a road warrior, and more of a strategic partner for the site they're working with," Vazquez observed. "We see now the advent of central monitoring teams where you have remote employees who can do a lot of the site monitoring reviews based on data coming in remotely."

This transformation reflects broader industry trends toward hybrid and remote work models that gained momentum during the pandemic, while also supporting more efficient resource allocation.

Strategic Implications for Industry

The findings come at a critical juncture for the clinical research industry, as organizations evaluate how to integrate emerging technologies like artificial intelligence while addressing fundamental operational inefficiencies.

"What a lot of people are trying to do now, because they have these mandates and they're trying to figure out how they take a complex thing like AI and stack it on top of an already complex process," Vazquez explained. "Stacking complexity on top of complexity is never going to yield you something that's more efficient or better. It's just going to make the problem worse."

The research suggests that successful modernization requires addressing foundational workflow issues before implementing advanced technologies. As Vazquez concluded, "Are we willing to take on the necessary change in order to make sure that our foundation is set?"

The study's findings have resonated across the industry, with presentations at the SCDM (搜索)搜索该词条 North America conference in Baltimore confirming that the identified inefficiencies are widespread and well-recognized among clinical data management professionals.